The management of Severe Asthma has been revolutionised recently by the advent of biologics or monoclonal antibodies targeting specific mediators of asthma. These are now routinely used in many countries around the world as part of treatment protocols. However they are expensive, so it is important to ensure that the right drug is given to the right patient. So, how do you know whether prescribing the patients will be beneficial?
In this episode of EUFOREA News, we have invited Prof. Milos Jesenak, EUFOREA asthma expert panel member and Professor of Paediatrics at the Jessenius Faculty of Medicine, Comenius University in Slovakia, and Prof. Vibeke Backer, EUFOREA asthma expert panel member and Chief Respiratory Physician in the Department of ENT and the Centre for Physical Activity Research at Rigshospitalet, in Copenhagen, in Denmark, to provide us with a paediatric and adult perspective in this matter.
Learn more here: www.euforea.eu...
Prof. Milos Jesenak
2:32 What is the situation in adolescent patients with asthma?
5:00 Are there specific clinical presentations to look for and/or biomarkers that allow the prediction of the success of biologics in adolescents with asthma?
5:45 What % of your severe asthma patients would be a candidate for biologics?
6:30 What do you predict as being the future of biological care for asthma in the paediatric population?
Prof. Vibeke Backer
8:08 Have the outcomes of biologics in severe asthma in adolescents changed?
9:00 How do you decide which biologic to use for which patient?
10:03 Are biomarkers helpful in predicting the success of biological treatment for severe asthma?
10:49 If patients have comorbidities, does that impact and drive the choice for one or the other biological?
11:35 Where do you see the future regarding the use of biologicals and the impact on patient care?
--------------------------------------------------------------------------------------------------------------------------
📽 Subscribe to our KZitem Channel for our latest videos on Allergies and Airway Diseases
bit.ly/3eMvc3E
--------------------------------------------------------------------------------------------------------------------------
📧 Get in touch with the EUFOREA team for any questions
bit.ly/2OtlIQp
--------------------------------------------------------------------------------------------------------------------------
📌 EUFOREA is an international non-profit organisation forming an alliance of all stakeholders dedicated to reducing the prevalence and burden of allergies and airway diseases by implementing optimal patient care through education, research and advocacy. #euforea
📍Follow us on social media
Twitter: bit.ly/38wrrM7
LinkedIn: bit.ly/2OqtWsf
Instagram: bit.ly/3TGB5jM
Facebook: bit.ly/3cnNyFF
Негізгі бет Biologics in severe asthma: Prediction for success | Prof. Milos Jesenak and Prof. Vibeke Backer
Пікірлер